<DOC>
	<DOC>NCT01380678</DOC>
	<brief_summary>The purpose of this study is to evaluate that intralesional injection of bevacizumab on primary pterygium can reduce the corneal pterygium area, inflammation, redness and other symptoms.</brief_summary>
	<brief_title>Intralesional Bevacizumab Injection on Primary Pterygium</brief_title>
	<detailed_description>To evaluate the efficacy and safety of intralesional injection of bevacizumab on primary pterygium treatment</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Pterygium</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<mesh_term>Vasoconstrictor Agents</mesh_term>
	<mesh_term>Antazoline</mesh_term>
	<mesh_term>Histamine H1 Antagonists</mesh_term>
	<mesh_term>Histamine Antagonists</mesh_term>
	<criteria>primary pterygium previous ocular surgery</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>bevacizumab</keyword>
	<keyword>pterygium</keyword>
	<keyword>treatment</keyword>
	<keyword>elevation</keyword>
</DOC>